津巴布韦部分医疗机构中HIV阳性孕妇和哺乳期妇女对终身治疗(选项B+)的接受度:一项定性研究
Acceptability of lifelong treatment among HIV-positive pregnant and breastfeeding women (Option B+) in selected health facilities in Zimbabwe: a qualitative study.
作者信息
Chadambuka Addmore, Katirayi Leila, Muchedzi Auxilia, Tumbare Esther, Musarandega Reuben, Mahomva Agnes I, Woelk Godfrey
机构信息
Elizabeth Glaser Pediatric AIDS Foundation, 107 King George Road, Avondale, Harare, Zimbabwe.
Elizabeth Glaser Pediatric AIDS Foundation, Washington DC, USA.
出版信息
BMC Public Health. 2017 Jul 25;18(1):57. doi: 10.1186/s12889-017-4611-2.
BACKGROUND
Zimbabwe's Ministry of Health and Child Care (MOHCC) adopted 2013 World Health Organization (WHO) prevention of mother-to-child HIV transmission (PMTCT) guidelines recommending initiation of HIV-positive pregnant and breastfeeding women (PPBW) on lifelong antiretroviral treatment (ART) irrespective of clinical stage (Option B+). Option B+ was officially launched in Zimbabwe in November 2013; however the acceptability of life-long ART and its potential uptake among women was not known.
METHODS
A qualitative study was conducted at selected sites in Harare (urban) and Zvimba (rural) to explore Option B+ acceptability; barriers, and facilitators to ART adherence and service uptake. In-depth interviews (IDIs), focus group discussions (FGDs) and key informant interviews (KIIs) were conducted with PPBW, healthcare providers, and community members. All interviews were audio-recorded, transcribed, and translated; data were coded and analyzed in MaxQDA v10.
RESULTS
Forty-three IDIs, 22 FGDs, and five KIIs were conducted. The majority of women accepted lifelong ART. There was however, a fear of commitment to taking lifelong medication because they were afraid of defaulting, especially after cessation of breastfeeding. There was confusion around dosage; and fear of side effects, not having enough food to take drugs, and the lack of opportunities to ask questions in counseling. Participants reported the need for strengthening community sensitization for Option B+. Facilitators included receiving a simplified pill regimen; ability to continue breastfeeding beyond 6 months like HIV-negative women; and partner, community and health worker support. Barriers included distance of health facility, non-disclosure of HIV status, poor male partner support and knowing someone who had negative experience on ART.
CONCLUSIONS
This study found that Option B+ is generally accepted among PPBW as a means to strengthen their health and protect their babies. Consistent with previous literature, this study demonstrated the importance of male partner and community support in satisfactory adherence to ART and enhancing counseling techniques. Strengthening community sensitization and male knowledge is critical to encourage women to disclose their HIV status and ensure successful adherence to ART. Targeting and engaging partners of women will remain key determinants to women's acceptance and adherence on ART under Option B+.
背景
津巴布韦卫生与儿童保健部(MOHCC)采用了2013年世界卫生组织(WHO)预防母婴传播艾滋病毒(PMTCT)指南,建议对艾滋病毒呈阳性的孕妇和哺乳期妇女(PPBW)开始进行终身抗逆转录病毒治疗(ART),无论其临床阶段如何(方案B+)。方案B+于2013年11月在津巴布韦正式启动;然而,终身抗逆转录病毒治疗的可接受性及其在女性中的潜在接受情况尚不清楚。
方法
在哈拉雷(城市)和兹温巴(农村)的选定地点进行了一项定性研究,以探讨方案B+的可接受性、抗逆转录病毒治疗依从性和服务接受的障碍及促进因素。对PPBW、医疗服务提供者和社区成员进行了深入访谈(IDI)、焦点小组讨论(FGD)和关键信息提供者访谈(KII)。所有访谈均进行了录音、转录和翻译;数据在MaxQDA v10中进行编码和分析。
结果
进行了43次IDI、22次FGD和5次KII。大多数女性接受终身抗逆转录病毒治疗。然而,她们担心承诺终身服药,因为她们害怕停药,尤其是在停止母乳喂养后。在剂量方面存在困惑;还担心副作用、没有足够的食物服药以及在咨询中没有提问的机会。参与者报告需要加强对方案B+的社区宣传。促进因素包括接受简化的服药方案;能够像艾滋病毒阴性女性一样在6个月后继续母乳喂养;以及伴侣、社区和卫生工作者的支持。障碍包括卫生设施距离远、不透露艾滋病毒感染状况、男性伴侣支持不足以及认识有抗逆转录病毒治疗负面经历的人。
结论
本研究发现,方案B+在PPBW中普遍被接受,作为增强她们的健康和保护其婴儿的一种手段。与先前的文献一致,本研究证明了男性伴侣和社区支持在令人满意地坚持抗逆转录病毒治疗和加强咨询技巧方面的重要性。加强社区宣传和男性知识对于鼓励女性透露其艾滋病毒感染状况并确保成功坚持抗逆转录病毒治疗至关重要。在方案B+下,针对并让女性的伴侣参与进来仍将是女性接受和坚持抗逆转录病毒治疗的关键决定因素。
相似文献
J Assoc Nurses AIDS Care. 2018
引用本文的文献
本文引用的文献
SAHARA J. 2013-6-28